Have a feature idea you'd love to see implemented?
Let us know!
OGEN Oragenics Inc
Price (delayed)
$0.383
Market cap
$2.14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.54
Enterprise value
$788,784
Oragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against
Highlights
The debt has dropped by 100% since the previous quarter and by 100% year-on-year
Oragenics's net income has plunged by 63% YoY but it has increased by 3.7% from the previous quarter
OGEN's EPS is down by 30% year-on-year but it is up by 12% since the previous quarter
Oragenics's revenue has shrunk by 94% YoY and by 64% QoQ
The gross profit has dropped by 94% year-on-year and by 64% since the previous quarter
Key stats
What are the main financial stats of OGEN
Market
Valuations
Earnings
Shares outstanding
5.58M
Market cap
$2.14M
Enterprise value
$788,784
Price to earnings (P/E)
N/A
Price to book (P/B)
1.29
Price to sales (P/S)
232.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
105.65
Revenue
$7,466
EBIT
-$19.48M
EBITDA
-$19.48M
Free cash flow
-$7.15M
Per share
Balance sheet
Liquidity
EPS
-$7.54
Free cash flow per share
-$1.58
Book value per share
$0.3
Revenue per share
$0
TBVPS
$0.6
Total assets
$2.71M
Total liabilities
$1.38M
Debt
$0
Equity
$1.33M
Working capital
$235,646
Debt to equity
0
Current ratio
1.17
Quick ratio
0.97
Net debt/EBITDA
0.07
Margins
Efficiency
Dividend
EBITDA margin
-260,864.8%
Gross margin
100%
Net margin
-261,401.5%
Operating margin
-263,285.2%
Return on assets
-408.5%
Return on equity
-573.3%
Return on invested capital
-4,090.7%
Return on capital employed
-1,468.7%
Return on sales
-260,928.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OGEN stock price
How has the Oragenics stock price performed over time
Intraday
6.39%
1 week
-4.25%
1 month
-23.72%
1 year
-88.29%
YTD
-93.2%
QTD
0.47%
Financial performance
How have Oragenics's revenue and profit performed over time
Revenue
$7,466
Gross profit
$7,466
Operating income
-$19.66M
Net income
-$19.52M
Gross margin
100%
Net margin
-261,401.5%
The net margin has dropped by 166% since the previous quarter
The operating margin has plunged by 165% from the previous quarter
Oragenics's revenue has shrunk by 94% YoY and by 64% QoQ
The gross profit has dropped by 94% year-on-year and by 64% since the previous quarter
Growth
What is Oragenics's growth rate over time
Valuation
What is Oragenics stock price valuation
P/E
N/A
P/B
1.29
P/S
232.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
105.65
OGEN's EPS is down by 30% year-on-year but it is up by 12% since the previous quarter
Oragenics's equity has plunged by 82% YoY and by 49% from the previous quarter
The P/B is 56% less than the last 4 quarters average of 2.9 and 44% less than the 5-year quarterly average of 2.3
Oragenics's revenue has shrunk by 94% YoY and by 64% QoQ
The stock's price to sales (P/S) is 33% less than its last 4 quarters average of 349.2
Efficiency
How efficient is Oragenics business performance
OGEN's return on sales has dropped by 166% since the previous quarter
The company's return on invested capital has shrunk by 52% QoQ
OGEN's ROE is down by 38% from the previous quarter
OGEN's ROA is down by 25% since the previous quarter
Dividends
What is OGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OGEN.
Financial health
How did Oragenics financials performed over time
The total assets is 96% more than the total liabilities
Oragenics's current ratio has shrunk by 84% YoY and by 57% QoQ
The company's quick ratio has shrunk by 83% YoY and by 57% QoQ
The debt is 100% smaller than the equity
The debt has dropped by 100% since the previous quarter and by 100% year-on-year
OGEN's debt to equity has shrunk by 100% QoQ and by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.